“…In the past decade, numerous preclinical studies have reported promising in vitro and in vivo activity of CAR T cells targeting various myeloid antigens in human AML cells and patient-derived xenograft (PDX) models, including Lewis-Y, 52 CD33, 53–59 CD123, 35,47,50,51,54,60–64 CD44v6, 49 the folate receptor β, 65 CD38, 66,67 and the FLT3 receptor (CD135), 68–70 and CLL-1 (CLEC12A). 71–73 All of these targeted CAR T cells have demonstrated potent in vitro cytotoxicity and cytokine production when incubated with antigen-positive AML cell lines or primary cells (Table 1).…”